Stocktoria
SANGAMO THERAPEUTICS, INC SGMO
OTC · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2000-04-06
SANGAMO THERAPEUTICS, INC (SGMO) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend. FY2025 revenue was $39.6M at a -310.8% net margin.
2/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Price from month-end closes (Yahoo) — for reference, not real-time.
Market cap$72M
Net margin-310.8%
Revenue trend · last 10y · up
How it ranks in Manufacturing · percentile among 1829 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Detailed pages
Sector peers · similar-size Manufacturing companies
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SGMO | SANGAMO THERAPEUTICS, INC | 2/9 | — | — | -31.6% |
| KYMR | Kymera Therapeutics, Inc. | 3/9 | 9.79 | — | -16.7% |
| VYGR | Voyager Therapeutics, Inc. | 1/9 | -1.03 | — | -49.5% |
| EDIT | Editas Medicine, Inc. | 1/9 | — | — | +25.4% |
| CHRS | Coherus Oncology, Inc. | 4/9 | — | 1.4 | +59.8% |
| CCCC | C4 Therapeutics, Inc. | 3/9 | -2.12 | — | +1% |
| XFOR | X4 Pharmaceuticals, Inc | 3/9 | -1.48 | — | — |
FAQ
Is SGMO financially healthy?
SANGAMO THERAPEUTICS, INC's Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does SGMO pay a dividend?
No, SANGAMO THERAPEUTICS, INC does not currently pay a dividend.
How profitable is SGMO?
In FY2025, SANGAMO THERAPEUTICS, INC had a net margin of -310.8%.
Source: SEC EDGAR filings · CIK 0001001233 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.